Effects Of Interferon On126Newborns With Respiratory Syncytial Virus Pneumonia

Objective: To determine the efficacy and safety of interferon-α1b inthe treatment of neonatal respiratory syncytial virus pneumonia.Method:286newborns with respiratory syncytial virus pneumoniawere divided into treatment group and control groups.126patients intreatment group were given interferon-α1bintramuscularly(1μg·kg-1·d-1).Both groups received the same generaltreatments such as oxygen therapy, nebulization, antibiotics and so on.Manifestations remission time, oxygen use and the length of hospital stay intwo groups were analyzed retrospectively.Result:1.There was no significant difference between two groups in generalinformation(P>0.05).2.All neonates with respiratory syncytial virus pneumonia showedmanifestations such as cough(93.0%),polypnea(90.1%), cyanosis(67.8%),choking milk(62.9%)and moist rales(58.4%).No difference was noted in theclinical findings mentioned above(P>0.05).3.The percentage of co-infected by bacteria was66.8%(191/286).The main bacteria included Escherichia coli (21.5%), Klebsiellapneumonia(20.4%), Staphylococcus aureus (17.2%), Acihetobacterbaumanii (13.1%) and pseudomonas aeruginosa (9.9%)。The constituentratio of bacteria in treatment group was similar to that in control group(P＞0.05).4. The remission time of cough, polypnea, Choking milk, cyanosis,moist rales and oxygen use in the treatment group was shorter than controlgroup, which were significantly different (P<0.05). Although the length ofhospital stay in the treatment group was shorter than control group, thedifference wasn’t significant(P>0.05).5. Two cases of treatment group fevered in2-6hours after receivinginterferon-α1b.No other adverse effects were observed in all cases.Conclusion: Interferon-α1b could improve clinical feature withoutapparent side effects in treating neonatal respiratory syncytial viruspneumonia.